Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
about
Calcium channel blockers for primary Raynaud's phenomenonCalcium channel blockers for primary Raynaud's phenomenonOral vasodilators for primary Raynaud's phenomenonRaynaud's Phenomenon: A Brief Review of the Underlying MechanismsRaynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementRecent achievements in the management of Raynaud's phenomenon.Advances in the treatment of Raynaud's phenomenon.Raynaud's phenomenon (secondary).Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available TreatmentCurrent treatment options in systemic Sclerosis (Scleroderma).Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus.Treatment of scleroderma: an update.Old medications and new targeted therapies in systemic sclerosis.Mechanisms of Raynaud's disease.Therapeutic options for digital ulcers in patients with systemic sclerosis.Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.The challenge of scleroderma ulcers.The pathogenesis, diagnosis and treatment of Raynaud phenomenon.The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.Scleroderma therapy: clinical overview of current trends and future perspective.Treatment of Raynaud phenomenon in systemic sclerosis.Targeted therapies for systemic sclerosis.Optimal management of digital ulcers in systemic sclerosisConsensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.Current and future direction in the management of scleroderma.Management of Pain Associated with Selected Conditions in Dermatology.Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves.The role of platelets in the pathogenesis of systemic sclerosis.Raynaud's phenomenon and vitamin D.Three-grade classification of photoplethysmography for evaluating the effects of treatment in Raynaud phenomenon.Evidence-based management of Raynaud's phenomenon.Fluoxetine and Raynaud's phenomenon: friend or foe?European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.Risperidone Related Raynaud's Phenomenon: An Adolescent Case.Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis.
P2860
Q24186106-08AB44D1-69B0-48EC-A109-C3CF7935612BQ24200938-C76F7C86-3798-400E-A1E2-462D3D797473Q24202210-099027BE-413D-4A1C-9074-BE687A286EECQ28067805-6686BE8B-1F8A-4499-BDC1-E08F54B5032BQ28392431-DFCED635-AF4E-4529-ABE0-F7EF77BF9575Q33797622-86E1AFD2-6E25-418E-A0A6-ED7C68400EDDQ33813778-0A02E180-7758-48A0-89E5-120B2CCA5E5BQ34011187-46C5B5FB-01EA-411B-9EC9-AB09BA84BB67Q34548029-92A84700-98F0-445D-B954-FCBCBCCDA2E3Q34567929-1652D9CC-2C97-4412-8A92-B3E12D44BF51Q34583641-FEBDF469-CB4B-4219-8012-737429576AA5Q35073374-CA421136-53CE-4FA4-996D-A41ECC3AC255Q36154430-A66332A5-8B4C-4937-A538-48FBF6765019Q36380983-E7897FDC-0153-4692-B159-DDD17104885BQ36835012-A1727B78-05A8-4FDA-B271-68A5A9993C74Q37030669-9E4EF61B-4C78-4661-A3DA-67FB50C534ADQ37500626-F3D23A1D-D3CB-4EF0-AB07-FC76B1E865CEQ38025285-BD5E56D9-BD42-4D01-BF87-83DE575DC504Q38042445-17DA1CF5-0894-4F49-BAFC-ACCA716970B0Q38046467-608D430F-C5AC-4510-A5BE-EAB190232A98Q38076483-BFCABBEF-D0F4-4463-8296-2AC5743FFEABQ38097276-5486FD33-3A77-4784-ABDF-ED9A2AAB2C97Q38537531-06C5D36F-7A92-4C1D-921A-A10218037F03Q38538817-38E9CDC4-EA6E-449A-AECF-B8A6D22EA2CCQ38823948-1042F050-9074-49A7-A750-82F087E8AF17Q38852222-D92686C7-8F72-4E4F-92A7-4AF01C1CCE0FQ39461570-CAAADBB2-9C37-43FC-8C17-16726E08CC5EQ39806660-C7998814-BDE7-451E-B687-FC984B020FFEQ40586588-6AAC526B-EB83-45F1-BE56-A867E8026074Q42203442-15BD1633-D68D-4147-A5B3-F4FFEE1927E4Q45342518-D038C2FE-12B6-4A50-AA62-5000DCBAD83BQ46097229-1F93DDC1-D9C7-44C3-A461-F7AD51A9290EQ47803000-949A6547-FF28-4201-B62D-F05D355D112EQ48330196-3DEBD74E-AFBC-4AFC-8604-6E5F573430E3Q49072027-0E93C8E9-ABD5-4BE0-AD6A-931B26AFC618Q49348691-3B20979F-C113-4E12-A697-F409C6E0364FQ50243982-CB2C883A-4B30-4B1C-B0E3-27AA16DE83CBQ52374296-4C6685FC-81C9-4437-86BF-6025B62B2250
P2860
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@en
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@nl
type
label
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@en
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@nl
prefLabel
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@en
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@nl
P2093
P2860
P356
P1433
P1476
Treatment of Raynaud's phenome ...... reuptake inhibitor fluoxetine.
@en
P2093
Marshall SE
P2860
P304
P356
10.1093/RHEUMATOLOGY/40.9.1038
P577
2001-09-01T00:00:00Z